Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19)

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 5, 2010, Pages 2163-2171

  Charbonnel, Bernard ^a   DeFronzo, Ralph ^b   Davidson, Jaime ^c   Schmitz, Ole ^d   Birkeland, Kare ^e   Pirags, Valdis ^f   Scheen, André ^g  

^a HÔTEL DIEU   (France)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c MEDICAL CITY DALLAS HOSPITAL   (United States)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e AKER UNIVERSITY HOSPITAL   (Norway)

^f PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^g UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; STROKE; TREATMENT OUTCOME; WEIGHT GAIN; BLOOD; BLOOD PRESSURE; BODY MASS; DIABETIC ANGIOPATHY; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; HYPERTENSION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 77952749448     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1974     Document Type: Article

References (25)

1. Kahn SE 2003 The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3-19 (Pubitemid 36237741)
2. U.K. Prospective Diabetes Study Group 1995 U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258
3. Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M 2005 Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetología 48:1093-1104 (Pubitemid 40909644)
4. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, for the QUARTET Study Group 2004 One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27:141-147 (Pubitemid 38196723)
5. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
6. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B 2006 Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963-1972
7. Scheen AJ, Lefèbvre PJ 1998 Oral antidiabetic agents. A guide to selection. Drugs 55:225-236
8. Yki-JärvinenH2004 Thiazolidinediones.N Engl J Med 351:1106-1118
9. Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW 1998 Troglitazone use in insulin-treated type 2 diabetic patients. Diabetes Care 21:1455-1461 (Pubitemid 28405196)
10. Strowig SM, Avilés-Santa ML, Raskin P 2004 Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 27:1577-1583
11. Strowig SM, Avilés-Santa ML, Raskin P 2002 Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 25:1691-1698
12. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM 1999 A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 48:2414-2421
13. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J 2001 A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. The Rosiglitazone Clinical Trials Study Group. Diabetes Care 24:1226-1232 (Pubitemid 33716403)
14. Davidson JA, Perez A, Zhang J; The Pioglitazone 343 Study Group 2006 Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab 8:164-174
15. Raz I, Stranks S, Filipczak R, Joshi P, Lertoft B, Rastam J, Chow CC, Shaban J 2005 Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Clin Ther 27:1432-1443
16. Rosenstock J, Einhorn D, Hershon K, Glazer NB, YuS 2002 Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebocontrolled study in patients receiving stable insulin therapy. The Pioglitazone 014 Study Group. Int J Clin Pract 56:251-257
17. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366:1279-1289
18. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS 1993 Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 16: 21-31
19. Bergenstal RM 2006 Treatment models from the International Diabetes Center: advancing from oral agents to insulin therapy in type 2 diabetes. Endocr Pract 12:98-104 (Pubitemid 44963622)
20. Juurinen L, Kotronen A, Granér M, Yki-Järvinen H 2008 Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J Clin Endocrinol Metab 93:118-124
21. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA 2001 Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719
22. DeFronzo RA, Ferrannini E, Simonson DC 1989 Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38:387-395
23. U.K. Prospective Diabetes Study (UKPDS) Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
24. United Kingdom Prospective Diabetes Study Group 1998 United Kingdom Prospective Diabetes Study 24. A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 128:165-175
25. Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm Jr RH, Probstfield JL, Simons-Morton DG, Friedewald WT, Action to Control Cardiovascular Risk in Diabetes Study Group 2008 Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559